Quick Answer
Pelthos Therapeutics Inc. reported R&D Expense of $1.23 million for fiscal year 2025.
Pelthos Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.23M | +4.2% |
| 2024 | $1.18M | -54.3% |
| 2023 | $2.58M | +558.5% |
| 2022 | $391.7K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $145.0K | -65.1% | -71.8% |
| June 30, 2025 | $514.8K | +3873.9% | +165.0% |
| March 31, 2025 | $194.3K | -58.4% | -53.2% |
| September 30, 2024 | $415.0K | +744.7% | +3103.4% |
| June 30, 2024 | $13.0K | -74.1% | -97.2% |
| March 31, 2024 | $466.6K | +150.7% | +849.7% |
| September 30, 2023 | $49.1K | — | -1.6% |
| June 30, 2023 | $50.0K | — | -73.2% |
- Pelthos Therapeutics Inc. showed an increase of +4.2% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Pelthos Therapeutics Inc.’s r&d expense has grown by 213.5% (from $391.7 thousand to $1.23 million).
- The most recent figure is from Pelthos Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: